2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. LDLR

LDLR

Low-density lipoprotein receptor

The low-density lipoprotein receptor (LDLR) gene family includes LDLR, very LDLR, and LDL receptor-related proteins (LRPs) such as LRP1, LRP1b (aka LRP-DIT), LRP2 (aka megalin), LRP4, and LRP5/6, and LRP8 (aka ApoER2). LDLR family members constitute a class of closely related multifunctional, transmembrane receptors, with diverse functions, from embryonic development to cancer, lipid metabolism, and cardiovascular homeostasis.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P10911
    IETP2
    		Ligand
    IETP2 targets low-density lipoprotein receptor-related protein 1 (LRP1) with a KD of 738 nM and can be used for drug- and imaging agents delivery across the blood-labyrinth barrier (BLB).
    IETP2
  • HY-P10698
    VH-N412
    VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.
    VH-N412
  • HY-105961
    F 2833
    		Inhibitor
    F 2833 is a lipid-lowering agent. F 2833 can reduce the levels of cholesterol, triglycerides, and plasma phospholipids. F 2833 can be used for research on diseases such as hyperlipidemia.
    F 2833
  • HY-161941
    MeIm
    MeIm (compound 7) is a high-affinity PCSK9 targeting peptide mimetic with cholesterol-lowering activity. MeIm increases cellular uptake of LDL (EC50=6.04 μM) by inhibiting the binding of PCSK9 to LDLR (IC50=11.2 μM). MeIm can be used in the study of cardiovascular diseases.
    MeIm
  • HY-126551
    Butenoyl-PAF
    Butenoyl-PAF is a phospholipid analog of platelet activating factor (PAF-like) that is generated in oxidized low-density lipoprotein (DLDR). Butenoyl-PAF can activate cells that express human PAF receptors, such as neutrophils, monocytes, and platelets, and it stimulates an increase in intracellular calcium ion concentration.
    Butenoyl-PAF
  • HY-18778A
    Obicetrapib sodium
    		Inhibitor
    Obicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
    Obicetrapib sodium
  • HY-167870
    Piceatannol 4'-O-glucoside
    		Inhibitor
    Piceatannol 4'-O-glucoside is an antioxidant. Piceatannol 4'-O-glucoside is active against oxidation of the human LDL. Piceatannol 4'-O-glucoside can be isolated from Mexican Bamboo.
    Piceatannol 4'-O-glucoside
  • HY-P11452
    (KKEEE)3K
    (KKEEE)3K is a kidney-targeting peptide. (KKEEE)3K enters renal tubular cells via megalin receptor-mediated endocytosis. (KKEEE)3K can be used in the research of renal drug delivery.
    (KKEEE)3K
  • HY-172661
    Kylo-0603
    		Inhibitor
    KYLO-0603 is an orally active, selective THR-β agonist (EC50 : 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research.
    Kylo-0603
  • HY-B0374S
    Moxonidine-d4
    Moxonidine-d4 (BDF5895-d4) is the deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis.
    Moxonidine-d<sub>4</sub>
  • HY-123260
    S12340
    		Inhibitor
    S12340 is a a inhibitor of the oxidative modification of low-density lipoprotein and shows protective effect on cardiac cells exposed to oxidative stress.
    S12340
  • HY-B0374R
    Moxonidine (Standard)
    Moxonidine (Standard) is the analytical standard of Moxonidine (HY-B0374). This product is intended for research and analytical applications. Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis.
    Moxonidine (Standard)
  • HY-164412
    Phosphatidylcholine (C18:2,C20:4)
    		Activator
    Phosphatidylcholine (C18:2,C20:4) is a phospholipid that can be isolated from egg yolk.
    Phosphatidylcholine (C18:2,C20:4)
  • HY-B0374AR
    Moxonidine hydrochloride (Standard)
    Moxonidine hydrochloride (Standard) is the analytical standard of Moxonidine hydrochloride (HY-B0374A). This product is intended for research and analytical applications. Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis.
    Moxonidine hydrochloride (Standard)
  • HY-100144R
    Pirozadil (Standard)
    Pirozadil (Standard) is the analytical standard of Pirozadil. This product is intended for research and analytical applications. Pirozadil is a hypolipidemic agent.
    Pirozadil (Standard)
  • HY-161938
    BRD8518
    BRD8518 is a PCSK9 inhibitor (EC50=0.23 μM). BRD8518 lowers blood lipids by upregulating LDLR expression and stimulating LDL uptake. BRD8518 can be used in the study of cardiovascular diseases.
    BRD8518
  • HY-178335
    SGC-CK1γ-1
    		Inhibitor
    SGC-CK1γ-1 is a potent and selective probe for the CK1γ subfamily. SGC-CK1γ-1 can inhibit LRP6 phosphorylation levels. SGC-CK1γ-1 can selectively inhibit the CK1γ kinases in living cells and inhibit both WNT signaling and human cytomegalovirus (CMV) replication. SGC-CK1γ-1 can be used for the research of infection.
    SGC-CK1γ-1
  • HY-W007347R
    1,2-Cyclohexanedione (Standard)
    1,2-Cyclohexanedione is an endogenous metabolite.
    1,2-Cyclohexanedione (Standard)
  • HY-B0374S2
    Moxonidine-d3
    Moxonidine-d3 (BDF5895-d3) is deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis.
    Moxonidine-d<sub>3</sub>
  • HY-101529R
    Imanixil (Standard)
    Imanixil (Standard) is the analytical standard of Imanixil (HY-101529). This product is intended for research and analytical applications. Imanixil (HOE-402 free base) is an orally active LDL receptor (LDLR) inducer. Imanixil can reduce cholesterol levels by inhibiting VLDL-lipid production. Imanixil can delay atherosclerosis profession. Imanixil can be used for the research of cardiovascular disease, such as atherosclerosis.
    Imanixil (Standard)
Cat. No. Product Name / Synonyms Application Reactivity